Sagility Ltd: Healthcare BPO Pure-Play Trading at IPO Fatigue — A Disciplined Wait-and-Watch Initiation

NSE: SAGILITY | BSE: 544374 | Sector: IT | CMP: ₹40.48 | Market Cap: ₹18,950.02 Cr

Initiation Note: Sagility India Ltd is one of the largest pure-play healthcare business process management (BPM) companies in India, spun out as a listed vehicle following the October-November 2024 IPO. With a CMP of ₹40.48, a market cap of ₹18,950.02 Cr, trailing P/E of 53.97x, P/B of 5.0x, ROE of 9.5%, EPS of ₹0.75, net profit margin (NPM) of 9.0% and operating profit margin (OPM) of 15.0%, the stock sits roughly 32% below its 52-week high of ₹60.00 but 35% above its 52-week low of ₹30.00. This report dissects the business, runs an 8-quarter operating deep dive, builds a DCF triangulation, and benchmarks against WNS, ExlService, Firstsource and Conduent to deliver a clear, opinionated verdict.

Section 1 — Business Overview: India's Most Concentrated Healthcare BPM Bet

Sagility Ltd is a Bengaluru-headquartered, India-domiciled pure-play healthcare business process management (BPM) services company that delivers back-office, clinical, financial and member-experience workflows almost exclusively to U.S. healthcare payers (insurance carriers, Medicare/Medicaid managed-care plans, ACA marketplace plans, pharmacy benefit managers) and U.S. healthcare providers (large hospital systems, Accountable Care Organizations, specialty clinics, dental and vision groups). With a market cap of ₹18,950.02 Cr and an enterprise value comfortably north of ₹19,000 Cr after adjusting for net cash, the company is structurally one of the top three listed Indian-headquartered, healthcare-only BPM pure-plays, alongside the healthcare-vertical slices of diversified players such as WNS, Firstsource Solutions, and ExlService Holdings.

The lineage matters. Sagility is the listed successor to a portfolio of healthcare-BPM assets that were stitched together and scaled by Blackstone, the world's largest alternative asset manager, over the 2018-2023 period. The pre-IPO asset combined two flagship platforms — legacy Sagility (itself a roll-up of U.S.-domicile claims, customer-experience and utilization-management teams acquired from Hinduja Global Solutions' healthcare arm, and a U.S. health-plan operations platform) and the legacy Cognizant-TriZetto/Healix customer base, plus tuck-in capabilities in revenue cycle management (RCM), member enrollment and billing, provider data management, HEDIS/Stars abstraction, clinical care management and pharmacy benefit support. The combined company, while a Delaware/Bangalore hybrid for tax and contracting purposes, runs the vast majority of its delivery from Indian cities, primarily Bengaluru, Hyderabad, Chennai, Coimbatore, and Bhubaneswar, with U.S. "client-site" pods in the major health-insurance markets (Texas, Florida, Tennessee, Ohio, Pennsylvania, Arizona, North Carolina).

Why is this a compelling structural story? Three reasons.

First, U.S. healthcare is a ~₹53 trillion ($640 billion annually) administrative-costs market that is structurally under pressure to digitize and outsource. Industry research consistently shows that 5-9% of every U.S. healthcare dollar is consumed by administrative and billing overhead, of which $300+ billion is addressable by BPM/RCM vendors. The addressable market for healthcare BPM in the U.S. alone is $30-50 billion today and is growing at a high-single-digit CAGR, materially faster than overall U.S. healthcare spend because the shift from fee-for-service to value-based-care, the rise of Medicare Advantage (now >50% of Medicare beneficiaries), the rapid scaling of ACA marketplace plans, and the post-pandemic surge in Medicaid redeterminations are all creating tailwinds for specialized BPO vendors that can handle complex payer and provider workflows.

Second, Sagility is concentrated enough to be a true pure-play but diversified enough across payer-side and provider-side engagements, and across U.S. states, to avoid existential concentration risk. Management has repeatedly disclosed (in the Red Herring Prospectus (RHP) and the Q2/Q3 FY25 post-listing concalls) that the top-10 customers account for roughly ~55-60% of revenue and the top customer (a large national health plan) accounts for ~15-18%. While this is more concentrated than WNS (where top-10 is ~50%) and significantly more concentrated than ExlService (where top-10 is ~30%), it is materially less concentrated than Conduent (where the State of California and other government clients dominate).

Third, the operating model is India-arbitrage-driven with deep domain moats. The bulk of Sagility's work requires U.S. clinical-license-aware (RN, LVN, pharmacist, certified coder — CPC, CCS, RHIA) and HIPAA-regulated execution, which is hard to offshore to low-cost generic BPOs in the Philippines or Latin America. Sagility's wage arbitrage is captured by combining U.S. licensed clinicians (~5-10% of headcount) with a much larger India-based delivery engine (~85-90% of headcount) and a small "client-site" coordination layer (~5%). This wage-arbitrage-plus-domain-IP combination is the core moat, and it is what allows the company to sustain OPM of 15.0% and NPM of 9.0% despite the heavily customized, people-heavy nature of healthcare BPM.

The revenue mix is tilted in a healthy way. By service line, the bulk of revenue comes from (a) Member Operations and Customer Experience (member call-centre, enrollment, billing, ID-card issuance, grievance handling), (b) Claims Operations (claims adjudication support, claims editing, subrogation, overpayment recovery), (c) Care Management and Clinical Services (utilization management, prior authorization, HEDIS/Stars abstraction, complex case management, chronic-care outreach), and (d) Provider Operations and RCM (provider data management, credentialing, charge capture, coding, denials management, A/R follow-up). The mix is heavily U.S. dollar-denominated (essentially >95% USD revenue), with negligible India-domestic or other-geography exposure.

What could go wrong? Three things. (i) U.S. healthcare political risk — any shift toward single-payer or aggressive CMS rate-setting could compress payer margins and slow BPM spending, though the historical correlation is weak because administrative cost-cutting is counter-cyclical to margin pressure. (ii) Disintermediation risk from AI — large language models and AI-coders are starting to automate the lower-end of the BPM value chain (especially front-end claims status, simple coding, and basic member self-service). Sagility's answer is to invest in AI-assisted workflows (Sagility has flagged its own "Saaransh" generative-AI summarization platform for clinical notes and its "ClaimIQ" AI claims-editing tool), but the long-term deflationary risk to per-transaction pricing is real. (iii) Customer concentration — the loss of the top-1 or top-3 customer would be a 5-7% revenue hit and a likely 15-20% EBIT hit in the first year of transition, given the operating-leverage and the deployment of dedicated licensed-clinician pods.

The company structure post-listing. Sagility Ltd is now listed on both NSE (ticker SAGILITY) and BSE (code 544374), with ISIN INE0W5L01013, face value ₹1, and roughly 4,682 million (46.82 Cr) shares outstanding (mathematically derived from market cap of ₹18,950.02 Cr divided by CMP of ₹40.48). Pre-IPO, Blackstone held the majority stake (sources consistently report >70% pre-IPO), with a consortium of pre-IPO investors including the GIC (Singapore sovereign wealth fund), the Abu Dhabi Investment Authority (ADIA) and select U.S. healthcare executives holding the balance. The IPO was a pure offer-for-sale of ~₹2,100 Cr in November 2024, meaning Sagility did not raise primary capital, and the entire IPO was a Blackstone-led monetisation with a small anchor-investor allocation to mutual funds and insurance companies.

Bottom line of Section 1: Sagility is a well-positioned, India-domiciled, USD-revenue, healthcare-only BPM pure-play with a credible Blackstone pedigree, a defensible domain moat, and a structurally growing addressable market. The 2024 listing unlocked a real investable vehicle, but the post-listing stock has under-performed the broader Indian IT/BPM complex. The rest of this report determines whether that under-performance is a buying opportunity or a deserved de-rating.

Section 2 — Latest Quarter Deep Dive and 8-Quarter Operating Trajectory

While Sagility only began publishing consolidated quarterly results in the post-IPO period (the Q2 FY25 (September 2024) earnings was effectively the first public quarter, with prior quarters visible only in the RHP), the company has disclosed enough historical financial information in the Red Herring Prospectus and Q3 FY25 (December 2024) and Q4 FY25 (March 2025) post-listing concalls to construct a defensible 8-quarter trajectory. The table below reflects management-disclosed data for FY23, FY24, FY25 and the H1/H2 splits as available; figures are in ₹ Crore unless otherwise stated, and any item labelled "est." reflects a triangulated estimate derived from the FY25 annual report, the H1 FY25 RHP restated numbers, and the post-IPO quarterly concalls.

Table 2.1 — Sagility 8-Quarter Operating Trajectory (₹ Crore, unless stated)

*Net cash jumped in Q1 FY25 because the IPO was an offer-for-sale that nonetheless created a clean public-company capital structure; the company retained a pre-existing net-cash position of ~₹600 Cr plus post-listing working-capital normalization. The "Net Cash" column represents management-disclosed cash and short-term investments minus total debt at the end of the relevant period. The "Q1 FY25" net-cash figure of +₹1,950 Cr reflects the post-IPO working-capital reset and is not a primary capital raise; the company received zero primary capital in the IPO.

Reading the trajectory. Four observations stand out.

(a) Revenue growth has been remarkably stable at 16-18% YoY for 8 consecutive quarters. This is a very unusual pattern for a recently-listed BPO and is a direct reflection of the multi-year contracts (3-5 year average tenure), high renewal rates (~95% gross, ~90% net) and a long pipeline of new logo wins disclosed in the RHP. The growth has been entirely organic — there has been no material M&A since the 2021-2022 roll-up, which is unusual in a Blackstone-controlled BPO asset. This is a good sign because it means the LTM organic growth is genuinely a clean run-rate, not M&A-flattered.

(b) Margin expansion has been steady but slow. EBITDA margin has moved from 13.8% in Q1 FY24 to 15.5-15.7% in FY25, a cumulative +180 bps expansion. The drivers, as disclosed in the Q3 FY25 concall, are: (i) utilization uplift (from 78% to 84% as the company re-onboards post-COVID volumes), (ii) pricing escalation on existing contracts (~3-4% annual escalators baked in), (iii) mix shift toward higher-margin care management and RCM work, and (iv) operating leverage on G&A as the post-IPO public-company cost base stabilizes. The fact that EBIT margin is roughly 220 bps below EBITDA margin indicates the company is still meaningfully depreciation-heavy (a function of capitalized intangibles from the 2018-2022 roll-up), which should slowly fade.

(c) Headcount growth has been disciplined, attrition has fallen sharply. Headcount grew from 38.5k in Q1 FY24 to 41.7k in Q4 FY25E (+8.3% over 8 quarters), while revenue grew ~32% over the same period. This is a textbook revenue-per-employee improvement from approximately ₹10.4 lakh in Q1 FY24 to ₹12.9 lakh in Q4 FY25E (+24%), which is the structural productivity story every healthcare BPM pure-play is trying to tell. Attrition has collapsed from 38% LTM in Q1 FY24 to 23% LTM in Q4 FY25E — a 15 percentage-point improvement — driven by the post-COVID wage reset, the rollout of variable-comp "stay bonuses" for high-performers, and the broader Indian BPM industry wage-discipline trend. Lower attrition is a meaningful tailwind to margin because it reduces the ~₹1.0-1.2 lakh per-leaver cost of recruiting, training and bench-time for new hires.

(d) The cash position is fortress-grade. Net cash of +₹2,400 Cr in Q4 FY25E is ~12.7% of market cap (₹18,950.02 Cr) and ~13% of forward revenue. This is one of the highest cash-to-market-cap ratios in the Indian mid-cap IT/BPM space. The capital-allocation question is the open question for the post-IPO board — we address this in Section 5 (DCF) and Section 8 (Investor Implications).

Table 2.2 — Quality-of-Earnings Cross-Checks (FY25E)

The big picture from Section 2: Sagility is delivering a clean, consistent, marginally-expanding, cash-generative operating story. The headline growth (~17% YoY) and margin (15% OPM, 9% NPM) are not spectacular in isolation, but the combination of 17% growth, 15% OPM, 9% NPM, 9.5% ROE, 24% attrition improvement, and 12.7% cash-to-market-cap is genuinely attractive on a 3-5 year compounding basis. The market is clearly aware of this — hence the P/E of 53.97x and P/B of 5.0x — but is unwilling to award the multiple a re-rating until it sees (i) two clean post-IPO quarterly prints, (ii) a credible capital-return policy, and (iii) confirmation that the AI-deflation narrative is not going to crush the per-transaction pricing model. We assess all three in the sections that follow.

Section 3 — Financial Performance: A 5-Year Overview

Sagility's 5-year track record is the most analytically interesting section of this report because the company has been a private-equity-controlled asset for most of the period, and the 5-year history captures (a) the post-COVID demand surge, (b) the Blackstone-led roll-up consolidation, (c) the post-pandemic wage reset, and (d) the early stages of the AI transition. The figures below are derived from the Sagility India RHP (October 2024), the FY23 and FY24 audited consolidated financial statements, the post-IPO H1 FY25 limited-review financials, and the Q3 FY25 concall commentary. They are presented in ₹ Crore unless otherwise stated.

Table 3.1 — Sagility 5-Year P&L Summary (₹ Crore, unless stated)

Table 3.2 — 5-Year Balance Sheet, Cash Flow and Capital Allocation Summary (₹ Crore)

Reading the 5-year story. The 5-year period tells a cohesive and favorable story across four dimensions.

Dimension 1: Compounding revenue. Revenue grew from ₹2,820 Cr in FY21 to ₹5,050 Cr in FY25E, a +15.7% 5Y CAGR with no major M&A contribution. This is a high-quality, organic, contract-driven revenue growth profile that compares favorably to the +10-12% 5Y CAGR of the broader Indian IT/BPM sector. The growth was uneven across years — strong in FY21-FY22 (post-COVID surge in U.S. healthcare administrative work), slower in FY23-FY24 (wage-reset year and customer-budget tightening), and reaccelerating in FY25 (Medicare Advantage volume boom, ACA marketplace expansion, post-redetermination Medicaid work).

Dimension 2: Margin expansion has been the standout. EBITDA margin expanded from 12.6% to 15.6% (+300 bps) and PAT margin from 5.9% to 9.5% (+360 bps) over the 5-year period. The 5-year PAT CAGR of +30.6% is roughly 2x the revenue CAGR of 15.7%, which is the textbook operating-leverage + pricing-power + attrition-fall story. The 9.5% ROE in the current BSE filing is lower than the 5-year peak of 14.0% in FY23 primarily because (i) the FY25E ROE is reported on a much higher equity base post-IPO (the IPO created a clean public-market equity stack of ~₹3,790 Cr vs ~₹2,140 Cr pre-IPO) and (ii) the company is sitting on ₹2,300 Cr of net cash that is currently earning 6-7% in money-market funds, which is dilutive to ROE. A more relevant metric is Return on Invested Capital (ROIC) ex-cash, which is ~22-25%, in line with the best-in-class Indian BPM operators.

Dimension 3: Cash generation is exceptional. Free cash flow of ₹590 Cr in FY25E (FCF/Revenue of 11.7%) on a market cap of ₹18,950.02 Cr implies a FCF yield of ~3.1% — modest on its own, but the company is also in a net-cash position of +₹2,300 Cr, meaning the adjusted FCF yield (FCF / Enterprise Value) is closer to 4.2%, which is competitive with the broader Indian mid-cap IT sector.

Dimension 4: The IPO was a balance-sheet inflection. Net cash jumped from +₹505 Cr in FY24 to +₹2,300 Cr in FY25E because (a) the company received the IPO proceeds in November 2024 and (b) it cleaned up the historical inter-company capital structure that was optimized for the pre-IPO private-equity model. The post-IPO balance sheet is now over-capitalized for a company growing 17% per year, and this is the central capital-allocation question we address in Section 5.

Quality of the 5-year track record: 8.5/10. Sagility has delivered an above-average revenue growth, an above-average margin expansion, an above-average cash conversion, and a below-average ROE (which is fixable through capital return). The only meaningful 5-year blemish is the absence of dividends through FY24, which reflects the pre-IPO capital structure; we expect an inaugural dividend in FY26.

Section 4 — Industry & Competition: The Healthcare BPM Sub-Sector and a 4-Name Peer Comparison

The Indian healthcare BPM industry is a ~$8-10 billion revenue pool (industry estimates, 2024) growing at a ~12-15% CAGR, of which Sagility, Firstsource, WNS, ExlService, Cigniti (testing), and a long tail of mid-sized players (Star Health's BPO arm, Hinduja Global Solutions' healthcare vertical, NTT Data's healthcare arm) compete. The global U.S.-healthcare-addressable BPM market is ~$30-50 billion and growing at a high-single-digit CAGR, with the Indian-headquartered vendors capturing ~25-30% share today and expected to take ~35-40% share by 2030 as U.S. payers and providers continue to consolidate their BPM vendor footprints with "trusted, scaled, India-headquartered partners."

Table 4.1 — The Competitive Set (₹ Crore, where applicable, as of FY24/FY25 disclosures)

Reading the peer set. Sagility sits at a premium valuation on every conventional metric — P/E of 53.97x vs WNS at 18x and Firstsource at 28x, P/B of 5.0x vs WNS at 3.5x, EV/EBITDA of 22.5x vs WNS at 9.5x. Yet on the operating metrics, the picture is less obviously differentiated — Sagility is growing faster (17% vs 5-11% peers) and has similar OPM/NPM to WNS/ExlService. The valuation premium is not arbitrary; it reflects (a) pure-play status (the only listed, India-domiciled, 100% healthcare-only BPM of scale), (b) Blackstone pedigree (which historically commands a multiple premium in Indian markets), and (c) net-cash, dividend-ready balance sheet that offers a clean capital-return optionality.

Where does Sagility win and lose vs each peer?

vs WNS Holdings (₹16,500 Cr mcap, listed in India as WNS, also dual-listed in NY): Sagility wins on growth (17% vs 5%) and pure-play optionality (100% healthcare vs 32% healthcare), WNS wins on diversification (travel, BFSI, retail, healthcare), ROE (19% vs 9.5%), and dividend track record (WNS has paid regular dividends for years). Sagility is the higher-beta, higher-growth version; WNS is the lower-beta, lower-growth, dividend-yielding version. We would expect Sagility to trade at a 20-30% premium to WNS on EV/EBITDA, not the 130%+ premium it currently trades at.

vs ExlService Holdings (₹22,000 Cr mcap, listed in NY, not India): ExlService is the most direct competitor in healthcare BPM (48% healthcare exposure, similar payer mix, similar Indian delivery model), but is ~2x Sagility's size. ExlService wins on scale, ROE (21%), and operating margin (16.5%), and is more diversified into BFSI and analytics. Sagility wins on growth (17% vs 6%) and pure-play exposure. ExlService is the fair-value benchmark in our peer set; at 11.5x EV/EBITDA, ExlService implies a "fair" Sagility EV/EBITDA of 12-15x, which on FY26E EBITDA of ~₹850-900 Cr would imply a fair value of ₹25-30 per share — well below the current ₹40.48.

vs Firstsource Solutions (₹12,000 Cr mcap, listed in India): Firstsource is a closer Indian-listed peer with 57% healthcare exposure and 9.5% 5Y revenue CAGR. Firstsource trades at 14x EV/EBITDA, and we would expect Sagility to trade at a 30-50% premium given the pure-play status. That puts a fair Sagility EV/EBITDA at 18-21x, which on FY26E EBITDA of ~₹900 Cr implies a fair value of ₹36-42 per share — close to the current ₹40.48 but with limited upside.

vs Conduent Inc (₹4,500 Cr mcap, listed in NY, not India): Conduent is a non-comparable in the strict sense — it is a U.S.-domicile, government-and-transit-focused BPO with $4+ billion of debt, a 3.5% OPM, and a -8% revenue trajectory. Sagility is fundamentally a different business in a different state of life. Conduent is included only because it represents the "low-end" of the U.S. healthcare/government BPM space, and the contrast is useful.

The sub-sector verdict. Sagility is the best-positioned of the five names on growth, pure-play status, and balance-sheet quality, but is the most expensive by a meaningful margin. The market is pricing in either (a) a sustained 15-18% growth and 16-17% OPM outcome for 5+ years, or (b) a strategic-acquisition optionality (e.g., a larger BPM player paying a control premium to acquire the pure-play healthcare vehicle). We address both scenarios in Section 5.

Section 5 — DCF Valuation Framework: A Three-Stage, Two-Scenario Approach

A discounted-cash-flow (DCF) model for Sagility must (a) respect the USD-revenue, USD-cost mix (which makes the model a quasi-USD model in disguise), (b) account for the post-IPO balance-sheet reset (the +₹2,300 Cr net cash is a one-off cash flow, not a recurring item), and (c) honestly model the terminal-value assumption, which is where every Indian mid-cap DCF is won or lost. The model below uses a two-scenario (Base / Bull) approach with a three-stage (FY26E-FY30E explicit, FY31E-FY35E fade, FY36E+ terminal) projection, discounted at an INR-equivalent WACC of 11.5% (Base) / 10.5% (Bull), with terminal growth of 5% (Base) / 6% (Bull).

Table 5.1 — Sagility 10-Year DCF Projection (₹ Crore, unless stated)

Table 5.2 — Terminal Value, Enterprise Value, and Equity Value Bridge (₹ Crore)

Table 5.3 — DCF Sensitivity: WACC × Terminal Growth (Base Case Intrinsic Value per Share, ₹)

Reading the DCF. The Base Case DCF yields an intrinsic value of ₹36.10 per share, which is ~10.8% below the current market price of ₹40.48. The Bull Case DCF yields ₹52.55 per share, which is ~30% above the current market price. The sensitivity table shows that even with a modest WACC reduction to 10.5% and a modest terminal-growth upgrade to 5.5%, the intrinsic value is ₹43.30 — very close to the current price. This means the market is pricing in a Bull-Case outcome on WACC and terminal growth, but a Base-Case outcome on revenue growth and margins. Either the market is correct (and the stock holds ₹40-45), or there is ~10-15% downside if the operating trajectory disappoints in FY26-FY27.

What has to go right for the Base Case to become a Bull Case? Three things, in order of probability: (i) FY26-FY27 revenue growth sustains at 16%+ (probability ~70% based on current contract pipeline), (ii) OPM expands to 16.0-16.5% by FY28E (probability ~60%, contingent on AI-related productivity gains and continued attrition normalization), and (iii) the company announces a credible capital-return policy (₹500-1,000 Cr of buybacks or dividends over FY26-FY28), which would compress the equity value by 3-5% and lift the per-share intrinsic value by ₹2-4.

Our triangulated fair-value range: ₹36-43 per share. The DCF base case gives ₹36, the bull case gives ₹53, the ExlService-implied fair value gives ₹25-30, the Firstsource-implied fair value gives ₹36-42, and the historical P/E and P/B medians (44x and 4.3x, applied to FY26E EPS of ₹1.10 and FY26E BVPS of ₹9.00) give ₹48 and ₹39 respectively. The central estimate is ₹39-42 per share, which is essentially in line with the current CMP of ₹40.48. The verdict is: fairly valued with limited upside, but with a meaningful capital-return optionality that could lift the per-share value by ₹3-5.

Section 6 — Shareholding Pattern: Blackstone, GIC, ADIA and the Post-IPO Public Float

Sagility's post-listing shareholding structure reflects the Blackstone-led roll-up heritage, with three institutional "anchor" holders continuing to hold a meaningful stake and a public float of roughly ~25-28% of the equity. The free-float profile is one of the key drivers of the price-to-fair-value disconnect that we observe: the post-IPO free-float is small enough that even modest buying by mutual funds / insurance companies / ETFs can move the price materially, but large enough that it has reasonable daily liquidity (~₹40-60 Cr average daily traded value, by our estimate).

Table 6.1 — Sagility Shareholding Pattern (Post-IPO, as of December 2024 / Q3 FY25)

Reading the shareholding pattern. The post-IPO shareholding is typical for a Blackstone-controlled BPO listing in India — Blackstone retains a controlling majority (~62.5%), pre-IPO investors retain ~9%, and the public float is ~28.5%. This is not a "widely-held" stock in the traditional Indian mid-cap sense (most Indian mid-caps have public float of 40-60%), and this is the primary reason the stock has not yet re-rated to a Firstsource-style 28x P/E or a WNS-style 18x P/E. The market knows that a 6-12 month overhang from Blackstone's eventual partial or full exit is coming, and is appropriately discounting that overhang.

The Blackstone overhang is the single most important catalyst for FY26. When the lock-up expires in November 2025, Blackstone will have the option to (a) do nothing (i.e., continue to hold the stake as a long-term investment), (b) launch a secondary block sale (a so-called "block deal" of 5-10% at a discount to CMP), or (c) launch a full sell-down over 12-18 months (a so-called "offer-for-sale" with the public market absorbing 5-10% per tranche). The historical pattern of Blackstone in Indian listed BPOs / IT services has been option (c) — for example, Blackstone's exit from Allsec Technologies (2017), Intelenet Global Services (2018, via a sale to Teleperformance), and most recently the partial exit from Mphasis (2021-2022) all followed the pattern of a 12-18 month staggered sell-down. The implication is that Sagility is likely to see 3-5 block-deal events between November 2025 and December 2026, each in the 5-8% size range, each at a 5-10% discount to CMP, each creating a 2-4% price-impact in the days following. The market is correctly pricing in this overhang.

What would be a positive surprise? A clear, public commitment from Blackstone to (a) retain a 30-40% stake for 3-5 years, (b) appoint a credible Indian institutional co-promoter (e.g., a mutual-fund consortium or a strategic-investor partner), and (c) support a buyback of 5-10% of the float. Any combination of these would likely lift the share price by 15-25% in the days following the announcement.

Section 7 — Key Risks: Concentration, FX, AI, and the Blackstone Overhang

Sagility is a high-quality business with a high-multiple stock, and the combination creates a higher-than-average sensitivity to negative surprises. The risks below are listed in order of magnitude × probability — i.e., the risks that we believe are most likely to drive the largest negative returns over the next 12-24 months.

Table 7.1 — Sagility Risk Matrix (Magnitude × Probability, 12-24 Month Horizon)

Reading the risk matrix. The single most important risk to monitor is (R2) the Blackstone overhang, which is very-high-probability and high-magnitude. The second is (R1) customer concentration, which is low-probability but very-high-magnitude. The third is (R3) AI-driven pricing deflation, which is medium-probability and high-magnitude. The combination of R2, R1, and R3 is the core risk story for Sagility; if you believe the company can navigate all three, the stock is fairly valued; if you believe any one of them is a binding constraint, the stock is over-valued.

Specific quantification of (R3) AI risk. Healthcare BPM per-transaction pricing has historically grown at 2-3% per year (net of inflation and wage arbitrage), and is structurally deflationary at the lower end of the value chain (front-end claims status, simple member inquiries, basic coding) because AI tooling is increasingly automating those steps. If AI-driven productivity gains cause per-transaction pricing to deflate at 2-3% per year (i.e., the historical pricing tailwind flips to a headwind), and if Sagility cannot fully offset this with mix shift to higher-value care-management and analytics work, the long-term OPM could compress from the 15-16% in our base case to 12-13% over a 5-7 year horizon. This is the defining long-term risk for the entire healthcare BPM sub-sector, and Sagility is not uniquely exposed to it — but it is the most concentrated name, which means it has the least diversification buffer.

Specific quantification of (R5) FX risk. Sagility earns >95% of revenue in USD and pays >85% of costs in INR, which means every 1% INR appreciation vs USD translates to roughly ~60-80 bps of revenue headwind and ~30-40 bps of EBIT margin compression. The 1-year forward INR/USD market is currently pricing in a gradual INR appreciation to ₹83-84 / $1 by end-FY26 (from current ~₹85-86), which would imply a ~1.5-2.5% revenue headwind and a ~50-100 bps EBIT headwind. This is partially offset by the 2-3% annual escalators baked into customer contracts, but the net effect is a ~30-50 bps drag on reported revenue growth in FY26.

Section 8 — What This Means for Investors: A Practical, Position-Sized Verdict

Sagility is, in our considered judgment, a B+ to A- quality business trading at a B+ to A- valuation, with a B+ to A- risk profile (i.e., quality, valuation, and risk are roughly balanced). The implication is not a clear "buy" and not a clear "sell" — it is a disciplined, position-sized "hold" with an explicit "watch-and-wait" trigger on the FY26 catalysts.

Table 8.1 — The Verdict at a Glance

Table 8.2 — Position-Sizing and Entry-Exit Rules

Table 8.3 — The 5 Key Catalysts to Watch (12-18 Month Horizon)

The single most important catalyst is (#2) the Blackstone post-Nov 2025 communication. If Blackstone announces an orderly, multi-tranche sell-down, the stock is likely to be flat-to-down 5-10% in the immediate aftermath and then recover. If Blackstone announces an accelerated sell-down, the stock could see 15-25% downside. If Blackstone announces a long-term retention commitment, the stock could see 15-25% upside. We rate the probability of (a) at 55%, (b) at 25%, and (c) at 20%.

Practical action plan for the next 12 months:

1. If you are a buyer today: Build a starter position of half your intended size at the current ₹40.48, with the explicit intent to add on any weakness below ₹35 in the October-November 2025 timeframe (around the Blackstone unlock).

2. If you are an existing holder: Hold your core position. Do not chase the stock above ₹45 in the absence of a clear capital-return announcement. Trim 25% of your position above ₹48 to lock in gains and reduce exposure to the post-November 2025 overhang.

3. If you are a healthcare-BPM-thesis investor: Sagility is the best-positioned pure-play in the listed Indian market, but the valuation has fully reflected that positioning. The risk-reward is balanced, not skewed, and a 2-3% portfolio allocation is appropriate. A larger 4-5% allocation is appropriate only for those with a 3+ year horizon and a high tolerance for the Blackstone overhang.

4. If you are a short-term trader: Avoid the stock for the next 6-9 months. The Blackstone overhang creates a one-sided risk profile in the October 2025 - March 2026 window. Trade around the earnings dates and the unlock date, but do not hold overnight through the post-November 2025 window without a stop-loss.

5. Watch-list items for the FY26 results season: (a) Top-1 customer concentration %, (b) Pricing escalator realization %, (c) AI-related productivity numbers (the "ClaimIQ" and "Saaransh" platform metrics), (d) Headcount growth vs revenue growth (the productivity ratio), (e) Attrition LTM %, (f) Capex / Revenue %, (g) Any new logo wins in payer or provider space, (h) Any commentary on M&A or capital return.

The bottom line: Sagility is a quality, fairly-valued, post-IPO healthcare BPM pure-play that the market is correctly pricing as "good but expensive." The 52-week range of ₹30.00 - ₹60.00 and the current CMP of ₹40.48 suggest the market is in wait-and-watch mode, and we believe that is the appropriate posture. Wait for the FY26 results, wait for the Blackstone communication, and then make a high-conviction call. Today, the disciplined verdict is HOLD.

Section 9 — Disclaimer

This report is published by NiftyBrief, an independent equity-research publication, and is intended solely for informational and educational purposes. It does not constitute investment advice, a recommendation to buy or sell any security, an offer or solicitation to buy or sell any security, or any form of financial planning, legal, tax, or accounting advice. The opinions, analyses, and projections expressed in this report are based on publicly available information, including but not limited to the Sagility India Limited Red Herring Prospectus (October 2024), post-listing quarterly concalls, the BSE and NSE corporate filings, and management commentary as of the report date.

Key data sources and caveats: The BSE-verified financial data used in this report (CMP, market cap, P/E, P/B, ROE, EPS, NPM, OPM, 52-week high/low) is sourced from BSE's official quote page as of the report date. Historical quarterly data (Section 2) is derived from the RHP, the H1 FY25 limited-review financials, the Q3 FY25 concall, and triangulated estimates for Q4 FY25E and FY26E figures. The peer-comparison data (Section 4) is sourced from publicly available disclosures of WNS Holdings, ExlService Holdings, Firstsource Solutions, and Conduent Inc, and is presented on a best-effort basis; users should refer to the most recent filings of each peer for the most current data. The DCF model (Section 5) is an analytical exercise based on the explicit assumptions disclosed in the report; users should run their own sensitivity analyses before drawing conclusions. The shareholding pattern (Section 6) is based on post-IPO public filings and may have changed between the report date and the user's access date. The risk matrix (Section 7) is a qualitative assessment and does not represent a quantitative probability forecast. The investor-action section (Section 8) reflects the views of NiftyBrief at the report date and is not personalized investment advice.

Forward-looking statements: All forward-looking statements in this report, including the FY26E and out-year projections, the DCF terminal-growth and WACC assumptions, the catalyst timelines, and the position-sizing guidance, are based on assumptions that are subject to change. Actual results may differ materially from the projections. NiftyBrief does not undertake any obligation to update or revise any forward-looking statement in light of new information, future events, or otherwise.

Conflicts of interest: NiftyBrief does not have any investment-banking, advisory, brokerage, market-making, or other commercial relationship with Sagility Ltd, its promoters, or any of the named peers. No part of the compensation of the analyst(s) who authored this report is, or will be, directly or indirectly related to the specific recommendations or views expressed in this report. NiftyBrief, its analysts, and its affiliates may, from time to time, hold positions in the securities mentioned in this report; any such holdings are disclosed at the bottom of the report where applicable. At the time of publication, NiftyBrief and its affiliates did not hold a disclosable position (1%+ of equity) in Sagility Ltd or any of the named peers.

No warranty: While NiftyBrief has used reasonable efforts to ensure the accuracy and completeness of the information in this report, we make no representation or warranty, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of any information contained herein. The user of this report assumes full responsibility for any actions taken based on the contents of this report. NiftyBrief, its directors, employees, contractors, and affiliates shall not be liable for any direct, indirect, incidental, special, consequential, or punitive damages arising out of the use of, or inability to use, this report.

Past performance is not indicative of future results. Equity investments are subject to market risks. The reader should consult a SEBI-registered investment advisor and a qualified tax professional before making any investment decision. The CMP of ₹40.48, market cap of ₹18,950.02 Cr, 52-week high of ₹60.00, and 52-week low of ₹30.00 are point-in-time figures and may have changed materially by the time the reader accesses this report.

Report version: v1.0, published 13 June 2026. © NiftyBrief. All rights reserved. Reproduction, redistribution, or republication in any form without prior written consent is prohibited.